Empowered Patient Podcast

David Bearss the Co-Founder, CEO and President of Halia Therapeutics, points out that despite traditional thinking, chronic inflammation is not just an unresolved acute inflammatory response. It has been discovered that a different pathway leads to the activation of this inflammatory response in diseases with components of chronic inflammation, such as Alzheimer’s disease, heart disease, COPD, psoriasis, IBD, and cancer. Their potential drug target is the NLRP3 inflammasome which has been identified as being associated with the activation of inflammation.

Blocking the Root Cause of Chronic Inflammation with David Bearss Halia Therapeutics